Drug supply shortage in Nigeria during COVID-19: efforts and challenges

Southern Med Review

article

Faiva, Edward¹  Ahmad, Shoaib²  Lucero-Prisno, Don Eliseo³  Hashim, Hashim Talib⁵  Ramadhan, Mustafa Ahmed⁵  Musa, Shingin Kovona¹  Bchara, John⁶  Tuama, Yahya Dheyaa⁵  Adebisi, Yusuff Adebayo⁷  Kadhim, Mustafa Hayder⁸  Essar, Mohammad Yasir⁹ 

[1] Faculty of Pharmaceutical Sciences, Ahmadu Bello University;Punjab Medical College;Department of Global Health and Development, London School of Hygiene and Tropical Medicine;Faculty of Management and Development Studies, University of the Philippines (Open University);College of Medicine, University of Baghdad;Faculty of Medicine, Tishreen University;Faculty of Pharmacy, University of Ibadan;College of Medicine, University of Kufa;Medical Research Center, Kateb University;Kabul University of Medical Sciences

关键词: COVID-19;    Drug shortage;    Nigeria;    Efforts;    Pharmaceutical;   

DOI  :  10.1186/s40545-021-00302-1

学科分类：药理学

来源: BioMed Central

【 摘 要 】

The COVID-19 pandemic has resulted in massive disruptions in global supply chains. Nigeria is particularly vulnerable with respect to pharmaceuticals since there is reduced local production and about 70% of the drug supply is imported creating a huge supply–demand disparity particularly in times like COVID-19. Nigeria is in need of huge quantities of quality-assured health commodities to effectively respond to the pandemic. Significant shortages of other essential medicines and medical products across the country could be imminent. Drug scarcity in Nigeria during the COVID-19 pandemic period is because of several accumulated factors, majorly as a result of global lockdown, decreased manufacturing, unaddressed regulatory affairs, poor access to resources by the population, lack of buffer stocks, security instability, and poor funding of the healthcare system. This situation if left unattended, could cause serious drawbacks to the health of the populace as well as the quality of life of Nigerians amid the COVID-19 Pandemic. Appropriate measures should be directed to ensure ethical processes on drug production, importation, pricing, and distribution to avoid such events during unavoidable scenarios, like the COVID-19 pandemic and other public health emergencies.

【 授权许可】

Unknown